Shenzhen OK Biotech Technology Co., Ltd. (SZOB)
Home > News > Content

Exemestane, CAS 107868-30-4 Reports: FDA Approves Cancer Treatment That Uses Virus To Attack Tumors

Exemestane, CAS 107868-30-4 reports: FDA approves cancer treatment that uses virus to attack tumors

John O’Donnell is in remission from melanoma thanks to a cancer-killing virus approved Tuesday by federal regulators.

This story was produced by Stat, a national publication from Boston Globe Media Partners that will launch online this fall with coverage of health, medicine, and life sciences.

Viruses are usually thought of as agents of disease. But for the first time, scientists are poised to bring to the US market a virus that can help thwart cancer, a development that could herald a new age of viral therapies.

Approved by the Food and Drug Administration on Tuesday for treating advanced-stage melanoma, the virus — called Imlygic, which was developed in part in a Massachusetts lab — is a modified version of the herpes virus that both attacks the cancer and sparks the immune system into action against tumors.

In clinical trials, it has helped some cancer patients achieve remission with few of the nasty side effects common to existing treatments. And as the first tumor-killing virus to receive the FDA’s blessing, Imlygic could accelerate the development of other viral therapies.

“This is huge for the whole field, and for cancer patients,” said John Bell, a senior scientist at the Ottawa Hospital Research 

Find more: Exemestane - Prescription drug, aromasin, aromasin exemestane, exemestane side effects, anastrozole, exemestane breast cancer, everolimus, everolimus exemestane, exemestane dosage, tamoxifen, 

Contact Us
Address: HK: 6/F,Fo Tan Industrial Centre,26-28 Au Pui Wan St,Fo Tan,Shatin,Hongkong Shenzhen: 8F, Fuxuan Building, No. 46, East Heping Rd, Longhua New District, Shenzhen, PRC China
Tel: +852 6679 4580
 Fax:+852 6679 4580
Shenzhen OK Biotech Technology Co., Ltd.(SZOB)